Head-to-head evidence
PEX168 vs TTP273
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
PEX168
Developed by Jiangsu Hengrui Pharmaceuticals and partners
NCT02477969 · Phase 3 · status unknown
This was a randomized, triple-blind, placebo-controlled trial with 587 participants, testing PEX168 against placebo, both added to metformin, using change in HbA1c as the primary measure. A published report of the trial's results describes the primary endpoint as met, with substantially more PEX168 patients than placebo patients reaching HbA1c targets at 24 weeks.
TTP273
Developed by vTv Therapeutics
NCT02653599 · Phase 2 · completed
In this randomized, double-blind, placebo-controlled trial of 174 participants, TTP273 lowered HbA1c by a statistically significant margin relative to placebo at both once-daily and twice-daily dosing, while HbA1c rose slightly in the placebo group.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: PEX168's landscape · TTP273's landscape